Cell membrane and cytoplasmic epidermal growth factor receptor expression in pancreatic ductal adenocarcinoma.
The significance of over-expression of epidermal growth factor receptor (EGFR) in pancreatic carcinoma is unclear. In this study, we examined the association between EGFR over-expression (membranous and cytoplasmic), the associated histopathologic features and clinical outcomes in post-resection pancreatic cancer patients. EGFR expression was determined immunohistochemically in 90 patients who underwent resection for pancreatic cancer. Cytoplasmic expression was considered positive if EGFR expression was seen in the cytoplasm in ≥ 10% of cells. Cell membrane staining was scored from 0 to 3+, with 2+ and 3+ being considered as membrane over-expression. Overall survival and progression-free survival were calculated using the Kaplan-Meier method, and survival curves were compared by the log-rank test. Out of 90 patients, 51 (57%) and 74 (68%) patients had membrane and cytoplasmic EGFR over-expression, respectively. There was a statistically significant correlation between cell membrane EGFR over-expression and lymph node positivity (P = 0.03). Patients with membrane EGFR over-expression had a shorter median progression-free survival (10.7 vs. 17.0 months, P = 0.02) and overall survival (15.9 months vs. 25.3 months, P = 0.17). Cytoplasmic EFGR over-expression was not significantly associated with recurrence or survival. Membrane EGFR over-expression in resected pancreatic cancer patients was associated with worse clinical outcomes than non-over-expression.
Department of Medical Oncology, Thomas Jefferson University, Bluemle Building 519, 233 South 10th St, Philadelphia, PA 19107, USA.
Amit
A
Mahipal
Mary J
MJ
Mcdonald
Agnieszka
A
Witkiewicz
Brian I
BI
Carr
D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000032:analysis; D021441:Carcinoma, Pancreatic Ductal / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D002462:Cell Membrane / Q000737:chemistry / Q000378:metabolism*; D003593:Cytoplasm / Q000737:chemistry / Q000378:metabolism*; D018572:Disease-Free Survival; D066246:ErbB Receptors / Q000096:biosynthesis*; D005260:Female; D049669:History, 16th Century; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D010190:Pancreatic Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D011379:Prognosis
D014408:Biomarkers, Tumor; C512478:EGFR protein, human; D066246:ErbB Receptors
Anticancer Res. 1997 Sep-Oct;17(5B):3841-7
9427790
Dig Surg. 2006;23(1-2):74-9
16717472
Eur J Cancer. 2001 Sep;37 Suppl 4:S9-15
11597399
Pancreas. 2004 Jul;29(1):e1-8
15211117
Anticancer Res. 1993 May-Jun;13(3):565-9
8317885
Int J Mol Med. 2003 Mar;11(3):305-9
12579331
Clin Cancer Res. 2002 Mar;8(3):734-44
11895903
Mol Cancer Ther. 2002 Aug;1(10):777-83
12492110
Cancer Res. 2009 Apr 1;69(7):2950-5
19276352
CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300
20610543
Cancer Res. 2000 Jun 1;60(11):2926-35
10850439
Int J Oncol. 2001 Oct;19(4):681-5
11562741
Hepatobiliary Pancreat Dis Int. 2002 Nov;1(4):620-3
14607699
Recent Results Cancer Res. 2003;162:115-32
12790326
Biologics. 2009;3:419-28
19774209
J Clin Oncol. 2004 Jul 1;22(13):2610-6
15226328
J Clin Oncol. 2007 May 20;25(15):1960-6
17452677
Langenbecks Arch Chir Suppl Kongressbd. 1998;115(Suppl I):69-72
14518215
Br J Cancer. 1993 Oct;68(4):808-12
8398712
J Pathol. 1992 Jan;166(1):7-12
1538276
Anticancer Res. 1998 Nov-Dec;18(6B):4613-9
9891528
Nihon Ika Daigaku Zasshi. 1992 Feb;59(1):51-61
1347773